BioSpace News Archive

Iterum Therapeutics plc, a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, announced results of its Annual General Meeting held on June 10, 2020.

Active Motif, a company with the vision of bringing the field of epigenetics into personalized medicine, announces access to a pre-print publication associated with their COVID-19 efforts in China to isolate, develop, and deliver high-value fully human recombinant SARS-CoV-2 antibodies to the market.

Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that it has entered into an at-the-market equity offering sales agreement with Canaccord Genuity LLC.

Abivax SA (Euronext Paris:FR0012333284 - ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that it has received € 5m in non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE - Prêts Garantis par l’Etat).

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) (“Adial” or the “Company”), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its lead drug candidate, AD04,

AIM ImmunoTech (NYSE American:AIM), today provided an update on the commercial launch of Ampligen® for the treatment of severe Chronic Fatigue Syndrome (CFS) in Argentina.

SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial

A study comparing short-term outcomes of minimally invasive (MI) lumbar decompression surgery to MI lumbar spine fusion surgery found no statistically significant difference in the amount of time patients needed to return to work.

Poor insulin handling associated with negative cardiovascular outcomes Preclinical data also presented showing MSDC-0602K restored pancreatic islet insulin content when used alone or in combination with liraglutide

Resumed surgical procedures and patient treatments have resulted in an urgent need for blood donations